MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.

European Journal of Haematology
Giovanni MarconiAntonio Curti

Abstract

Clinical response and chemosensitivity of relapse or refractory AML patients were evaluated after rescue and bridge-to-transplant MEC (mitoxantrone, etoposide, and cytarabine) regimen. Fifty-five consecutive AML patients were treated with MEC from 2009 to 2018. Chemosensitivity was evaluated by WT1 quantification. 27/55 patients (49.1%) had AML resistant to induction and 28/55 patients (50.9%) had AML relapse. 25/55 patients (45.5%) achieved a CR after one course of MEC, and 12 patients (21.8%) achieved WT1 negativity. In 12 patients, a second MEC was administered. Four out of 12 patients improved significantly their response with the 2nd MEC. MEC was an effective bridge to transplant, 32/55 patients (58.2%) received an allogenic stem cell transplant. Median overall survival (OS) from MEC was 455 days (95% CI 307-602 days.); patient with WT1 negative CR had the best OS (P<.000). WT1 is a useful marker of chemosensitivity after MEC as rescue and bridge-to-transplant therapy.

References

Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S AmadoriF Mandelli
Nov 1, 1989·European Journal of Haematology·M LazzarinoC Bernasconi
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E ArchimbaudP Travade
Nov 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M VignettiG Meloni
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
Sep 28, 2010·American Journal of Hematology·Holbrook E KohrtBruno C Medeiros
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
May 16, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FaderlHagop M Kantarjian
Oct 17, 2014·American Journal of Hematology·Elihu H Estey
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nelli BejanyanMei-Jie Zhang
Apr 9, 2015·Blood·Felicitas TholArnold Ganser
Sep 15, 2015·Bone Marrow Transplantation·T RuutuUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 26, 2015·American Journal of Hematology·Hagop Kantarjian
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Sep 8, 2016·The New England Journal of Medicine·Filippo MilanoColleen Delaney
Mar 14, 2017·Current Treatment Options in Oncology·Prithviraj BoseJorge E Cortes
Jun 8, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Byung-Sik ChoHee-Je Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Stan Deresinski
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi
Nobutoshi HagiwaraKiyohiko Yamashita
© 2021 Meta ULC. All rights reserved